
Switching to Three-Drug Regimen Maintains HIV Suppression
TOPLINE: Switching from a boosted protease inhibitor (bPI)–based regimen to bictegravir plus emtricitabine plus tenofovir alafenamide (B/F/TAF) maintained virological suppression over 48 weeks in patients with HIV who had preexisting resistance to …